RYE, N.Y., Aug. 9, 2013 /PRNewswire/ -- Curemark, a drug research and development company focused on neurological disorders, announced that the company has been awarded a new patent for its proprietary technology CM-1212 for the treatment of individuals with drug and alcohol addiction. The new patent, #8,486,390, is entitled "Pharmaceutical Preparation for the Treatment of the Symptoms of Addiction and Methods of Diagnosing the Same." It is the third in a series of patent grants for this indication.
"Physiological symptoms of drug and alcohol addiction involve impairments in protein breakdown caused by a lack of key enzymes. These symptoms have not been identified nor addressed in the current treatment and management of addiction," said Dr. Joan Fallon, Curemark founder and CEO. "The ability to identify and treat individuals with these contributory or resulting symptoms is a big step. We believe Curemark's findings on the effects of impairments in protein breakdown on the brain will provide new understanding of the complex factors of addiction."
Curemark is currently developing a treatment for autism, CM-AT, which the U.S. Food and Drug Administration (FDA) has granted its Fast Track designation. The FDA Fast Track program facilitates the development and expedites the review of new drugs that are intended to treat serious or life-threatening conditions, and that demonstrate the potential to meet unmet medical needs.
Curemark previously announced successful preliminary discussions with the FDA regarding the anticipated future filing of the company's New Drug Application (NDA) for CM-AT.
About Curemark LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about the company's innovative science, visit www.curemark.com
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
|SOURCE Curemark LLC|
Copyright©2012 PR Newswire.
All rights reserved